Dr. Edward Hu, also known as Ed, M.B.A., has been the Chief Financial Officer at WuXi AppTec Co., Ltd. and WuXi PharmaTech (Cayman) Inc. since August 2010. Dr. Hu has been Chief Investment Officer at WuXi PharmaTech (Cayman) Inc. since April 15, 2014. He serves as Chief Investment Officer at WuXi AppTec Co., Ltd., and served as its Chief Operating Officer since January 2008. He serves as Head of WuXi Corporate Venture Fund, spearheading the fund's investment strategy and portfolio management. Dr. Hu manages WuXi's finance, strategic investments, merger and acquisitions and new business building. In addition, he also manages WuXi's joint ventures with MedImmune and PRA. He is a Founding Partner at 6 Dimensions Capital. Dr. Hu served as Chief Operating Officer at WuXi PharmaTech (Cayman) Inc. from January 2008 to April 15, 2014. Dr. Hu served as an Interim Chief Financial Officer of WuXi PharmaTech (Cayman) Inc. from February 2009 to April 2010. He served as the Chief Financial Officer and Chief Operating Officer of WuXi AppTec from March 2009 to April 2014. He served as an Executive Vice President and Chief Operating Officer of WuXi AppTec from August 2007 to February 2009. He served on various roles to become a Senior Vice President and Chief Operating Officer of Tanox Inc. from October 2000 to July 2007. He has an extensive experience in operations and financial management. He served as the Executive Vice President of Operations for WuXi PharmaTech (Cayman) Inc., from August 13, 2007 to January 2008. Dr. Hu served as Senior Vice President and Chief Operating Officer of Tanox Inc., since February 1, 2006, where he managed operations, finance, IT, project management and strategic planning. He served as Vice President of Collaborative Projects and Internal Projects of Tanox Inc. from March 2004 to January 2005, Vice President of Operations since January 2005 and served as its Vice President of Financial Planning, Project & Portfolio Management. He served as director of Finance of Tanox Inc. from July 2002 until January 2004 and previously served as Associate Director of Financial Planning and Analysis from the time he joined Tanox in October 2000. From October 2000 to July 2007, he served at Tanox, Inc. and as its Director of Finance since 2000 and also an Associate Director of Financial Planning and Analysis. From 1996 to 1998, he served as Senior Financial Analyst of Merck & Co. Inc. Dr. Hu served as Manager of business planning at Biogen Idec, Inc., from 1998 to 2000, where he managed the business planning of R&D, Clinical Operations and Business Development Support and served as its Manager of Financial Planning and Analysis. He has been a Director and Board Observer of IDEAYA Biosciences, Inc. since May 2016. He is a Director of LifeMine Therapeutics, Inc. Dr. Hu serves as a founding member of board of directors at Vivace Therapeutics. He has been Director of WuXi AppTec since March 2016. He has been Non-executive Director at WuXi Biologics (Cayman) Inc. since February 27, 2014. He served as Director of Ambrx, Inc. until September 12, 2016. He completed his Ph.D. work, all but dissertation, in at Carnegie Mellon University. He holds an M.B.A. and M.S. in Chemistry from Carnegie Mellon University, Pittsburgh, Pennsylvania.